Advertisement
Australia markets closed
  • ALL ORDS

    7,405.60
    +20.90 (+0.28%)
     
  • ASX 200

    7,194.90
    +21.60 (+0.30%)
     
  • AUD/USD

    0.6580
    -0.0022 (-0.34%)
     
  • OIL

    71.26
    +1.92 (+2.77%)
     
  • GOLD

    2,020.80
    -25.60 (-1.25%)
     
  • Bitcoin AUD

    66,615.56
    -91.52 (-0.14%)
     
  • CMC Crypto 200

    914.81
    +18.10 (+2.02%)
     
  • AUD/EUR

    0.6110
    +0.0000 (+0.00%)
     
  • AUD/NZD

    1.0741
    +0.0049 (+0.46%)
     
  • NZX 50

    11,495.64
    -0.97 (-0.01%)
     
  • NASDAQ

    16,084.69
    +62.20 (+0.39%)
     
  • FTSE

    7,554.47
    +40.75 (+0.54%)
     
  • Dow Jones

    36,247.87
    +130.49 (+0.36%)
     
  • DAX

    16,759.22
    +130.23 (+0.78%)
     
  • Hang Seng

    16,334.37
    -11.52 (-0.07%)
     
  • NIKKEI 225

    32,307.86
    -550.45 (-1.68%)
     

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

Fulgent Genetics (NASDAQ: FLGT) has been a fascinating company to watch over the past few years. While that's an impressive market beat, there was a point in early 2021 when Fulgent's stock was up over 1,300%. This wild stock movement was spurred on by incredible revenue growth due to Fulgent's ability to pivot to providing COVID-19 tests early in 2020.